Stock Taper
SCREENER COMPARE ANY 2 STOCKS
JSPRW
JASPER THERAPEUTICS, INC.
NASDAQ
$0.01
▼ DOWN 36.67% (-0.00)

KEY STATISTICS

Market Cap$92.64 K
52w High$0.08
52w Low$0.01
Dividend Yield—
Frequency—
P/E—
Volume13.41K
Shares Out.16.25M

COMPANY

LEADERSHIP

Jeet Mahal
CHIEF EXECUTIVE
Jeet Mahal

COMPENSATION 2026

Salary$695,255
Stock Awards$0
Incentive Plan Pay$312,917
All Other Comp.$0
Total$3,369,990

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 6, 2026
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
22

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$12.00M
NOV
5
THU

PRICE

$0.01 ▼ DOWN 36.67% (−$0.00)
$0.01$0.01$0.01$0.019:34 AM10:31 AM11:27 AM12:24 PM1:21 PM2:17 PM3:14 PM0.01

About Jasper Therapeutics, Inc.

https://jaspertx.com ↗

Jasper Therapeutics, a Redwood City biotech, develops therapies for stem cell transplantation and gene editing, with lead candidate briquilimab targeting stem cell clearance before transplantation.

INDUSTRY

Biotechnology

A PRODUCT JASPER THERAPEUTICS, INC. IS KNOWN FOR

Briquilimab
Briquilimab

Briquilimab is Jasper Therapeutics' lead monoclonal antibody targeting KIT (CD117) to deplete mast cells, currently in clinical trials for CSU, CIndU, and asthma.

COMPETITORS

COMPETITOR
ALXO COMPARE
CLDX COMPARE

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
DIRECTOR
Shizuru Judith Anne
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
WIGGANS THOMAS G
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
Crutcher Patrick J
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
EMSTER KURT VON
Purchase · 7.5K shares
2026-07-31

SECTORS PEERS

PEERPRICE
INDP$1.14COMPARE
REVB$1.05COMPARE
ONCO$0.61COMPARE
PTIX$0.98COMPARE
ENVB$1.37COMPARE
SPRC$6.58COMPARE
SLXN$0.36COMPARE
SCNI$2.51COMPARE